ePrints

Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: A cost-effectiveness analysis

Lookup NU author(s): Professor Sir John BurnORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Women with germline BRCA1 mutation have a significant risk of breast and/or ovarian cancer. Prophylactic bilateral mastectomy (PBM) and prophylactic bilateral salpingo-oophorectomy (PBSO) prevent cancer in mutation carriers. The cost-effectiveness of PBSO (age of 35 years) with or without PBM five years earlier was compared to a no intervention setting employing a marginal cost analysis. National data on cancer incidence, mortality rates and costs were implemented together with observed Norwegian BRCA1 data in a Markov model and PBSO was assumed to reduce the risk of ovarian cancer by 90%. A 3% discount rate was used. The additional health care cost per mutation carrier undergoing PBSO and PBM was €15,784, and 6.4 discounted life years gained (LYG) was indicated (PBSO alone with 100% acceptance 3.1 LYG). The additional cost per LYG was €1973 (PBSO alone €1749/LYG). Including all resource use, the figure was a cost of €496 and €1284 per LYG, respectively. PBSO with or without PBM in BRCA1 mutation carriers is cost-effective. A testing of all incident breast cancers to identify mutation carrying families should be explored. © 2008 Elsevier Ltd. All rights reserved.

Publication metadata

Author(s): Norum J, Hagen AI, Maehle L, Apold J, Burn J, Moller P

Publication type: Article

Publication status: Published

Journal: European Journal of Cancer

Year: 2008

Volume: 44

Issue: 7

Pages: 963-971

ISSN (print): 0959-8049

ISSN (electronic): 1879-0852

Publisher: Pergamon

URL: http://dx.doi.org/10.1016/j.ejca.2008.02.025

DOI: 10.1016/j.ejca.2008.02.025

Altmetrics

Share